GT Biopharma (GTBP) AI Stock Analysis

• Market Cap: $14.52M
• Dividend Yield: N/A
• Average Volume (3M): 1.63M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.43
• Revenue Growth: N/A
• EPS Growth: 54.62%
• Country: US
• Employees: 1
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 31,553,892
• 10 Day Avg. Volume: 1,818,785
• 30 Day Avg. Volume: 1,629,462
• PEG Ratio: 0.02
• Price to Book (P/B): 0.75
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.34
• Enterprise Value/Market Cap: -0.13
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: 0.06
• 1Y Price Target: $3.00
• Price Target Upside: 310.96% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 41 Neutral
• Price Target: $0.40 ▼(-45.89% Downside)
• Action: Upgraded Date: 03/02/26
• Date: Action: Upgraded 03/02/26

The score is primarily weighed down by weak financial performance—no revenue, large ongoing losses, and persistent cash burn that imply continued financing needs. Technicals add pressure as the stock trades below major moving averages with negative MACD. Valuation contributes limited support because a negative P/E reflects unprofitability and no dividend yield is provided.

Positive Factors

Low Leverage

Minimal debt materially lowers financial distress and interest burden, providing durable flexibility. Over the next 2–6 months this makes non-dilutive debt or structured financing more accessible versus leveraged peers and reduces solvency risk while management advances clinical programs.

Platform-based Pipeline

A platform (TriKE/TetraKE) that directs NK cells supports multiple candidates and indications, creating scalable R&D optionality. Platform-derived assets improve partnership and licensing prospects, enabling outsized value capture if clinical proof emerges and sustaining pipeline productivity.

Improving Operating Loss Trend

A meaningful improvement versus 2021 suggests stronger cost discipline or program prioritization. If sustained, narrowing operating losses reduces cash burn, extends runway and lowers frequency of capital raises, improving the company's ability to execute clinical milestones over coming months.

Negative Factors

No Revenue & Heavy Losses

The company is pre‑commercial with persistent, sizable losses and negative cash flow, forcing continual external funding. Over 2–6 months this elevates dilution risk and constrains strategic options, as programs depend on successful financing or partnerships to maintain development timelines.

Eroding Shareholders' Equity

The decline to negative equity reflects cumulative losses that weaken the capital buffer. A compromised equity base limits the firm's ability to absorb clinical setbacks, reduces negotiating leverage for collaborations, and increases urgency for financing, amplifying long‑term execution risk.

Very Small Internal Team

Reporting a single employee indicates a skeletal internal organization reliant on CROs and partners. This elevates operational and execution risk for complex clinical programs, may slow decision cycles, and increases dependency on external vendors, which can affect program continuity and costs.

GT Biopharma Business Overview & Revenue Model

Company Description

GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I/II clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 TriKE fusion protein for cancer therapies; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California.

How the Company Makes Money

null

GT Biopharma Financial Statement Overview

Summary

Financials reflect a pre-commercial biotech profile: no revenue, persistent heavy losses (TTM EBIT -$12.4M; net loss -$34.4M) and sustained cash burn (TTM operating/free cash flow about -$12.9M). Low leverage with essentially no debt reduces balance-sheet risk, but equity has been pressured over time and was negative in 2024, highlighting ongoing funding dependence until revenue materializes.

Income Statement

TTM (Trailing-Twelve-Months) results show no revenue and continued heavy losses (EBIT of -$12.4M and net loss of -$34.4M). Losses have been persistent across years, with net income remaining negative in every annual period provided (e.g., -$13.2M in 2024 and -$7.6M in 2023), indicating the business has not yet demonstrated a repeatable earnings model. A positive is that operating loss levels have improved versus the very large 2021 loss, but profitability remains materially negative and volatile.

Balance Sheet

Leverage is very low with essentially no debt in TTM (Trailing-Twelve-Months) and 2024, which reduces financial risk. However, the equity base has been unstable—stockholders’ equity was negative in 2024 (-$1.7M) and has declined significantly from 2021 ($21.9M) to TTM (Trailing-Twelve-Months) ($5.8M). Returns on equity are highly negative in TTM (Trailing-Twelve-Months), reflecting that losses are eroding capital despite the light debt load.

Cash Flow

Cash generation remains weak with negative operating and free cash flow in every period shown, including TTM (Trailing-Twelve-Months) operating/free cash flow of about -$12.9M. Free cash flow improved modestly versus 2022, but it remains meaningfully negative and implies ongoing cash burn. With continued losses and cash outflows, funding needs likely remain elevated unless costs are reduced further or revenue ramps.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00	0.00	0.00
EBITDA	-34.32M	-13.16M	5.98M	-20.96M	-57.48M
Net Income	-28.35M	-13.16M	-7.60M	-20.88M	-58.01M
Balance Sheet
Total Assets	8.11M	4.23M	14.11M	16.74M	32.17M
Cash, Cash Equivalents and Short-Term Investments	6.81M	3.95M	13.97M	16.51M	31.98M
Total Debt	0.00	0.00	58.00K	174.00K	31.00K
Total Liabilities	2.32M	5.90M	6.63M	5.00M	10.26M
Stockholders Equity	5.79M	-1.67M	7.48M	11.73M	21.91M
Cash Flow
Free Cash Flow	-12.91M	-12.90M	-8.85M	-15.22M	-15.61M
Operating Cash Flow	-12.91M	-12.90M	-8.85M	-15.22M	-15.61M
Investing Cash Flow	0.00	12.89M	-2.01M	12.14M	-23.04M
Financing Cash Flow	15.78M	2.98M	6.27M	-224.00K	42.32M

GT Biopharma Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.73
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GTBP, the sentiment is Neutral. The current price of 0.73 is above the 20-day moving average (MA) of 0.45, above the 50-day MA of 0.54, and below the 200-day MA of 1.13, indicating a neutral trend. The MACD of -0.03 indicates Negative momentum. The RSI at 48.05 is Neutral, neither overbought nor oversold. The STOCH value of 62.55 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for GTBP.

GT Biopharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
DRMA	47 Neutral	$4.14M	-0.76	-203.36%	―	―	90.53%
TOVX	43 Neutral	$8.89M	-0.10	-209.36%	―	―	83.25%
REVB	42 Neutral	$4.43M	-2.23	-0.40%	―	―	96.26%
AZTR	42 Neutral	$4.58M	-0.12	-215.04%	―	-100.00%	93.82%
GTBP	41 Neutral	$14.52M	-0.15	-356.99%	―	―	54.62%